521 related articles for article (PubMed ID: 28532448)
1. The effects of a treatment combination of anti-VEGF injections, laser coagulation and cryotherapy on patients with type 3 Coat's disease.
Li S; Deng G; Liu J; Ma Y; Lu H
BMC Ophthalmol; 2017 May; 17(1):76. PubMed ID: 28532448
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of conbercept or ranibizumab intravitreal injection combined with laser therapy for Coats' disease.
Zhang L; Ke Y; Wang W; Shi X; Hei K; Li X
Graefes Arch Clin Exp Ophthalmol; 2018 Jul; 256(7):1339-1346. PubMed ID: 29549425
[TBL] [Abstract][Full Text] [Related]
3. Successful use of intravitreal ranibizumab injection and combined treatment in the management of Coats' disease.
Yang Q; Wei W; Shi X; Yang L
Acta Ophthalmol; 2016 Jun; 94(4):401-6. PubMed ID: 27150442
[TBL] [Abstract][Full Text] [Related]
4. Combination treatment of pediatric coats' disease: a bicenter study in Taiwan.
Lin CJ; Chen SN; Hwang JF; Yang CM
J Pediatr Ophthalmol Strabismus; 2013; 50(6):356-62. PubMed ID: 24669373
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab for Coats' disease with exudative retinal detachment and risk of vitreoretinal traction.
Ramasubramanian A; Shields CL
Br J Ophthalmol; 2012 Mar; 96(3):356-9. PubMed ID: 21653215
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal bevacizumab injections combined with laser photocoagulation for adult-onset Coats' disease.
Park S; Cho HJ; Lee DW; Kim CG; Kim JW
Graefes Arch Clin Exp Ophthalmol; 2016 Aug; 254(8):1511-1517. PubMed ID: 26631136
[TBL] [Abstract][Full Text] [Related]
7. Management of stage 3B Coats disease: presentation of a combined treatment modality and long-term follow-up.
Liang T; Peng J; Zhang Q; Zhu X; Xu Y; Zhao P
Graefes Arch Clin Exp Ophthalmol; 2020 Sep; 258(9):2031-2038. PubMed ID: 32474693
[TBL] [Abstract][Full Text] [Related]
8. [Adjuvant anti-VEGF therapy in Coats' disease].
Fiorentzis M; Stavridis E; Seitz B; Viestenz A
Ophthalmologe; 2015 May; 112(5):451-4. PubMed ID: 25134462
[TBL] [Abstract][Full Text] [Related]
9. Treatment of stage 3 Coats' disease by endolaser photocoagulation via a two-port pars plana nonvitrectomy approach.
Cai X; Zhao P; Zhang Q; Jin H
Graefes Arch Clin Exp Ophthalmol; 2015 Jul; 253(7):999-1004. PubMed ID: 25794987
[TBL] [Abstract][Full Text] [Related]
10. TRANSCLERAL DRAINAGE OF SUBRETINAL FLUID, ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR, AND WIDE-FIELD IMAGING-GUIDED LASER IN COATS EXUDATIVE RETINAL DETACHMENT.
Stanga PE; Jaberansari H; Bindra MS; Gil-Martinez M; Biswas S
Retina; 2016 Jan; 36(1):156-62. PubMed ID: 26355946
[TBL] [Abstract][Full Text] [Related]
11. Coats disease in 351 eyes: Analysis of features and outcomes over 45 years (by decade) at a single center.
Shields CL; Udyaver S; Dalvin LA; Lim LS; Atalay HT; L Khoo CT; Mazloumi M; Shields JA
Indian J Ophthalmol; 2019 Jun; 67(6):772-783. PubMed ID: 31124485
[TBL] [Abstract][Full Text] [Related]
12. Coats' disease: characteristics, management, outcome, and scleral external drainage with anterior chamber maintainer for stage 3b disease.
Yousef YA; ElRimawi AH; Nazzal RM; Qaroot AF; AlAref AH; Mohammad M; Abureesh O; Rejdak R; Nowomiejska K; Avitabile T; Toro MD; AlNawaiseh I
Medicine (Baltimore); 2020 Apr; 99(16):e19623. PubMed ID: 32311932
[TBL] [Abstract][Full Text] [Related]
13. Risk of Tractional Retinal Detachment Following Intravitreal Bevacizumab Along with Subretinal Fluid Drainage and Cryotherapy for Stage 3B Coats' Disease.
Bhat V; D'Souza P; Shah PK; Narendran V
Middle East Afr J Ophthalmol; 2016; 23(2):208-11. PubMed ID: 27162454
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of retinopathy of incontinentia pigmenti by anti-vascular endothelial growth factor].
Wang X; Liang JH
Zhonghua Yan Ke Za Zhi; 2019 Apr; 55(4):294-301. PubMed ID: 30982292
[No Abstract] [Full Text] [Related]
15. Outcomes of Anti-vascular Endothelial Growth Factor Treatment for Foveal Serous Retinal Detachment Associated with Inferior Staphyloma.
Lee EK; Yu HG
Korean J Ophthalmol; 2019 Jun; 33(3):228-237. PubMed ID: 31179654
[TBL] [Abstract][Full Text] [Related]
16. Anatomical and visual outcomes of ranibizumab injections in retinal pigment epithelium tears.
Erol MK; Ozdemir O; Coban DT; Ceran BB; Sari ES
Arq Bras Oftalmol; 2015; 78(3):168-72. PubMed ID: 26222106
[TBL] [Abstract][Full Text] [Related]
17. Integrating Scleral Buckling, Transscleral Drainage of Subretinal Fluid, Intravitreal Anti-Vascular Endothelial Growth Factor, and Laser Photocoagulation in Stage 3B Coats' Total Retinal Detachment.
Huang YC; Lai CC; Wu WC
Ophthalmic Surg Lasers Imaging Retina; 2016 Sep; 47(9):865-8. PubMed ID: 27631484
[TBL] [Abstract][Full Text] [Related]
18. EXTRAMACULAR FIBROSIS IN COATS' DISEASE.
Daruich A; Matet A; Tran HV; Gaillard MC; Munier FL
Retina; 2016 Oct; 36(10):2022-8. PubMed ID: 26991649
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Intravitreal Ranibizumab on the Surgical Outcome for Diabetic Retinopathy With Tractional Retinal Detachment.
Dong F; Yu C; Ding H; Shen L; Lou D
Medicine (Baltimore); 2016 Feb; 95(8):e2731. PubMed ID: 26937902
[TBL] [Abstract][Full Text] [Related]
20. Outcomes and prognostic factors for aggressive posterior retinopathy of prematurity following initial treatment with intravitreal ranibizumab.
Tong Q; Yin H; Zhao M; Li X; Yu W
BMC Ophthalmol; 2018 Jun; 18(1):150. PubMed ID: 29940900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
